Key Takeaways
- Clinical Bottom Line
- The Phenotypes of GERD
- Non-Erosive Reflux Disease (NERD)
- Erosive Esophagitis (EE)
Clinical Bottom Line
| GERD Phenotype | Pathological Features | Primary Management |
|---|---|---|
| NERD (Non-Erosive Reflux Disease) | Classic GERD symptoms but strict endoscopic absence of mucosal breaks or esophagitis. | Proton Pump Inhibitors (PPIs); High rate of PPI refractoriness indicating potential functional heartburn. |
| Erosive Esophagitis (EE) | Macroscopic mucosal breaks, ulceration, and exudate mapped by the Los Angeles (LA) Classification (Grades A-D). | High-dose PPI therapy for 8-12 weeks; strict surveillance for severe grades (C/D) to rule out Barrett’s Esophagus. |
| Barrett’s Esophagus (BE) | Metaplastic replacement of stratified squamous epithelium with intestinal columnar epithelium (goblet cells). | Long-term acid suppression; Endoscopic surveillance with Seattle Protocol biopsies; Radiofrequency Ablation (RFA) for dysplasia. |
| Refractory GERD | Persistent typical symptoms despite optimized, twice-daily double-dose PPI therapy. | Ambulatory pH-impedance testing to confirm acid/weakly-acidic reflux vs. functional esophageal disorder. |
The Phenotypes of GERD
Gastroesophageal Reflux Disease (GERD) is undoubtedly the most frequent diagnosis in outpatient gastroenterology, affecting nearly 20% of the Western population. However, viewing GERD as a single, monolithic disease entity is clinically obsolete. Advanced endoscopy and physiological testing have splintered the GERD diagnosis into distinct phenotypes with divergent treatment pathways and neoplastic risks.
Non-Erosive Reflux Disease (NERD)
NERD constitutes the vast majority (up to 70%) of all GERD presentations. These patients suffer from classic, debilitating heartburn and regurgitation, yet upon index endoscopy, the esophageal mucosa is perfectly pristine—there are no erosions, ulcers, or evidence of Barrett’s metaplasia (an LA Grade 0).
The NERD Clinical Challenge
The paradox of NERD is that patients often report more severe symptoms than patients with frank erosive esophagitis, yet they are significantly less responsive to standard PPI therapy. If a patient with presumed NERD fails to respond to an optimized PPI dose, ambulatory pH-impedance testing (e.g., Braxton-Hicks probe) is mandatory to rule out Functional Heartburn (where symptoms are driven by esophageal hypersensitivity, not aberrant acid exposure) or Eosinophilic Esophagitis (EoE).
Erosive Esophagitis (EE)
Erosive Esophagitis represents the classic, tissue-damaging manifestation of acid reflux, graded via the Los Angeles (LA) Classification:
- LA Grade A: One or more mucosal breaks ≤ 5 mm, not bridging the tops of mucosal folds.
- LA Grade B: Mucosal breaks > 5 mm, not bridging mucosal folds.
- LA Grade C: Mucosal breaks bridging the tops of mucosal folds, involving < 75% of the esophageal circumference.
- LA Grade D: Severe mucosal breaks involving ≥ 75% of the esophageal circumference.
Finding LA Grade C or D esophagitis mandates an automatic repeat upper endoscopy after 8 to 12 weeks of high-dose PPI therapy. Severe inflammation frequently masks the presence of underlying Barrett’s Esophagus, which can only be safely mapped and biopsied once the acute inflammatory erosions have healed.
The Risk of Barrett’s Esophagus (BE)
Barrett’s Esophagus is the adaptive, premalignant phase of chronic GERD, where the normal squamous lining is replaced by intestinal-type columnar epithelium to withstand the acidic environment. BE dramatically increases the risk of esophageal adenocarcinoma. While historically managed with life-long acid suppression and “watchful waiting,” modern 2026 guidelines aggressively employ Endoscopic Eradication Therapy (EET)—such as Radiofrequency Ablation (RFA) and Cryotherapy—to safely ablate BE segments that exhibit any degree of low or high-grade dysplasia, preventing progression to invasive carcinoma.
Clinical guidelines summarized by the Gastroscholar Research Team. Last updated: April 16, 2026. This article is intended for physicians and medical students.
